New: Explore the psychedelic pipeline via our Q3'25 šŸŽÆ Bullseye Charts.
You are currently viewing Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

VANCOUVER, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.Ā (the ā€œCompanyā€ or ā€œAlgernonā€) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the Canadian Intellectual Property Office (ā€œCIPOā€), No. 3101853, for the treatment of interstitial lung disease with NP-120 (ā€œIfenprodilā€), entitled ā€œCompositions and Methods for Treating Idiopathic Pulmonary Fibrosis.ā€

Source link

Leave a Reply

Subscribe to Our Free Newsletter